Hormone replacement therapy in women with postovariectomy syndrome and endometrial ablation

Abstract

The aim of the study was to estimate the efficacy and tolerance of hormone replacement therapy using Femoston 1/5 in women with postovariectomy syndrome who had undergone endometrial ablation. We examined 37 patients aged 47-52 years suffering from moderate and severe postovariectomy syndrome. All of them underwent endometrial ablation and bilateral adnexectomy due to recurrent endometrial hyperplasia and lack of effect from conservative therapy. During 1,5-2,5 years after operative treatment they received combined oestrogen-gestagen replacement therapy using Femoston 1/5. This preparation was shown to be highly effective for reduction of clinical presentations of postovariectomy syndrome. No influence on endometrial state was found.

Keywords

hormone replacement therapy / postovariectomy syndrome / endometrial ablatio

References

[1] Кулаков В.И., Юренева С.В., Майчук Е.Ю. Постовариоэктомический синдром. - М., 2003. — 19 с.

[2] Фемостон 1/5(монофазный режим). - М.: Solvay Pharma, 2002. - 44 с.

[3] Armstrong К., Popic S., Guerra C., Ubel P.A. Beliefs about breast cancer risk and of postmenopausal hormone replacement therapy. Med Decis Making 2000; 20: 308-13.

[4] Lomranz J., Becker D., Eyal N. et al. Attitudes towards hormone replacement therapy among middle-aged women and men//Eur. J. Obstet. Gynecol. Reprod. Biol. - 2000. - Vol. 93. - P. 199-203.

[5] Mattson L., Stadberg E., Milson I. Management of hormone replacement therapy: the Swedish experience//Eur. J. Obstet. Gynecol. Reprod. Biol. - 1996. - Vol. 64, Suppl. 1. - P. 3-5.

[6] Rabin D.S., Cipparrone N. Linn E.S., Moen M. Why menopausal women do not want to take hormone replacement therapy. Menopause 1999; 6: 61-7.

RIGHTS & PERMISSIONS

Eсо-Vector